Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 3 Multi-hit model for autoimmune diseases

Published byAlexia Ward Modified over 5 years ago

Similar presentations

Presentation on theme: "Figure 3 Multi-hit model for autoimmune diseases"— Presentation transcript:

1 Figure 3 Multi-hit model for autoimmune diseases
Figure 3 | Multi-hit model for autoimmune diseases. Clinical symptoms that occur after the initial hits in the development of autoimmune rheumatic disease still wane, whereas accumulation of hits leads to stable irreversible disease. Immune checkpoint inhibition (not shown) can be considered as a hit in this context, as checkpoint-blocking therapies cause immune-related adverse effects that resemble autoimmune phenomena in some patients. van der Vlist, M. et al. (2016) Immune checkpoints and rheumatic diseases: what can cancer immunotherapy teach us? Nat. Rev. Rheumatol. doi: /nrrheum

Download ppt "Figure 3 Multi-hit model for autoimmune diseases"

Similar presentations

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Response after initial increase in total tumour burden

Figure 2 Response after initial increase in total tumour burden
Figure 1 Role of innate lymphoid cells (ILCs) in steady state,

Figure 1 Role of innate lymphoid cells (ILCs) in steady state,
Figure 4 Tissue infiltration and lymphadenopathy in patients with CTLA4 mutations Figure 4 | Tissue infiltration and lymphadenopathy in patients with CTLA4.

Figure 4 Tissue infiltration and lymphadenopathy in patients with CTLA4 mutations Figure 4 | Tissue infiltration and lymphadenopathy in patients with CTLA4.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 3 Connexins in cartilage

Figure 3 Connexins in cartilage
Figure 1 Historical evolution of the clinical classification and

Figure 1 Historical evolution of the clinical classification and
Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.

Figure 1 Rheumatoid arthritis development over time in relation to the level of inflammation Figure 1 | Rheumatoid arthritis development over time in relation.
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 1 Induction of immune tolerance

Figure 1 Induction of immune tolerance
Figure 2 Binding properties of P2Y12-receptor inhibitors

Figure 2 Binding properties of P2Y12-receptor inhibitors
Figure 2 Heat map of targeted therapies in autoimmune diseases

Figure 2 Heat map of targeted therapies in autoimmune diseases
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum
Figure 4 Involvement of SEMA4D in the pathogenesis

Figure 4 Involvement of SEMA4D in the pathogenesis
Figure 2 Targeted versus untargeted metabolomics approaches

Figure 2 Targeted versus untargeted metabolomics approaches
Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases
Figure 1 Schematic comparison of expected

Figure 1 Schematic comparison of expected
Nat. Rev. Rheumatol. doi: /nrrheum

Nat. Rev. Rheumatol. doi: /nrrheum

Similar presentations

Ads by Google